InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.40
(
-0.05%
)
US TECH 100
18,311.80
(
0.46%
)
Dow Jones
39,284.83
(
-0.97%
)
Brent Oil
81.09
(
-0.55%
)
Bitcoin
67,776.58
(
-1.92%
)
Post# of 251908
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119681
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ghmm post# 76662

Thursday, 04/30/2009 6:16:49 PM

Thursday, April 30, 2009 6:16:49 PM

Post# of 251908
Tidbit from today’s ITMN CC re ritonavir:

In response to a question, Dan Welch said ritonavir boosting of ITMN-191 was not out of the question, but he couldn’t comment on it because such disclosures fall within Roche’s purview.

Welch’s comment contrasts with VRTX’s assertion on its EASL webcast that ritonavir has no value whatsoever in boosting Telaprevir.

Comments?


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up